Review Article:Redefining the R1 resection in patients with pancreatic ductal adenocarcinoma. (15th August 2016)

• Record Type: Journal Article
• Authors: Markov, Pavel; Satoi, Sohei; Kon, Masanori
• Is Part Of: Journal of hepato-biliary-pancreatic sciences. Volume 23:Number 9(2016)
• Page Start: 523
• Page End: 532
• Publication Date: 2016-08-15
• Subjects: Inking method -- Margin‐negative resection -- Pathological examination -- 1 mm‐rule; Liver -- Diseases -- Periodicals; Biliary tract -- Diseases -- Periodicals; Pancreas -- Diseases -- Periodicals; 617.556
• DOI: 10.1002/jhbp.374
• Languages: English
• ISSNs: 1868-6974

Abstract

Abstract: Most cases of pancreatic ductal adenocarcinoma (PDAC) are lethal. Margin‐negative surgical resection is a mainstay of treatment and the only chance of a cure. Differences in pathological reporting, surgical technique, definitions of resection margin, and group stratification all affect outcome analyses. Furthermore, there are controversial issues influencing the clinical interpretation of resection margin after pancreatectomy. There is no standardized definition of margin involvement in resected specimens of PDAC. The non‐standardized pathologic approach explains the wide range of positive resection margin rates (13–71%) that have previously been reported. A standardized pathologic evaluation needs to be developed for proper assessment of resection margin after oncologic pancreatectomy. This manuscript reviews the current controversial issues in assessing resection margin in order to enhance understanding of the current status and potential role of pathological evaluation in patients with PDAC. Abstract : Highlight Margin‐negative surgical resection is the mainstay of treatment in pancreatic cancer, but there is no standardized definition of margin involvement in resected specimens after pancreatoduodenectomy. Markov and colleagues review controversial issues in assessing the resection margin in order to elucidate the role of pathological evaluation in patients with pancreatic ductal adenocarcinoma.